Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TransThera to Start European Arm of Global Trial for Bile Tube Cancer

publication date: Mar 8, 2024

Nanjing TransThera was approved to begin a European Phase III trial of tinengotinib in patients with cholangiocarcinoma (CCA). CCA, a cancer in the tubes that carry the digestive fluid bile through the liver, is a rare but aggressive form of cancer. To be enrolled, patients must have FGFR-altered disease that is refractory/relapsed from chemotherapy or a FGFR Inhibitor. The European Phase III trial is part of a global study of the drug. Tinengotinib, a next-gen FGFR inhibitor, has shown potency against a variety of FGFR2 kinase domain mutations in Phase I and II trials for the CCA indication. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital